Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elicio Therapeutics (ELTX) Change in Accured Expenses (2020 - 2026)

Elicio Therapeutics filings provide 4 years of Change in Accured Expenses readings, the most recent being $306000.0 for Q4 2023.

  • On a quarterly basis, Change in Accured Expenses rose 230.21% to $306000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $2.2 million, a 826.56% increase, with the full-year FY2025 number at -$2.0 million, down 142.68% from a year prior.
  • Change in Accured Expenses hit $306000.0 in Q4 2023 for Elicio Therapeutics, down from $2.2 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $2.2 million in Q3 2023 to a low of -$2.2 million in Q4 2021.
  • Median Change in Accured Expenses over the past 4 years was $215000.0 (2023), compared with a mean of $351937.5.
  • Biggest five-year swings in Change in Accured Expenses: plummeted 223.49% in 2021 and later skyrocketed 1307.26% in 2023.
  • Elicio Therapeutics' Change in Accured Expenses stood at $1.8 million in 2020, then plummeted by 223.49% to -$2.2 million in 2021, then skyrocketed by 89.18% to -$235000.0 in 2022, then skyrocketed by 230.21% to $306000.0 in 2023.
  • The last three reported values for Change in Accured Expenses were $306000.0 (Q4 2023), $2.2 million (Q3 2023), and $124000.0 (Q2 2023) per Business Quant data.